Multiple approved medications , like copyright and Semaglutide, belong to the GLP-1 receptor agonist class . Primarily , these therapies are designed to mimicking endogenous substances that control blood glucose and promote slimming. Although copyright is a commercial product for type 2 diabetes

Individuals struggling with obesity are often faced with limited and sometimes ineffective treatment options. However, a groundbreaking new medication, Semaglutide, is rapidly changing the landscape of weight loss. Prescribed by regulatory bodies for chronic weight management, Semaglutide acts a